MK-7762

MK-7762 is an oxazolidinone compound with oral antitubercular properties. It acts by inhibiting MAO-B and the synthesis of mitochondrial proteins in mammals. In BALB/c mice models with acute and chronic tuberculosis infection, MK-7762 reduces bacterial load in the lungs, penetrates caseous necrotic lung lesions in C3HeB/FeJ mice, and maintains concentrations above the free MIC in those lesions. MK-7762 is applicable in tuberculosis research.

MK-7762 effectively inhibits 95% of Mycobacterium tuberculosis (Mtb) growth at a concentration of 0.93 μM over 7 days. It also impedes mammalian mitochondrial protein synthesis in HepG2 cells with an IC50 of 98 μM over 72 hours. Additionally, MK-7762 can eliminate 99% of H37Rv cells at 18.1 μM in 7 days. It inhibits MAO-B with an IC50 of 6.9 μM at a concentration of 10 μM.

MK-7762, administered orally at doses of (30-100 mg/kg; once or twice daily; for 12 consecutive days), effectively reduces lung bacterial load in BALB/c mice with acute infections. For chronic infections in BALB/c mice, MK-7762 (30-200 mg/kg; once daily; for 1 month) also decreases lung bacterial load. Additionally, MK-7762 (100 mg/kg; once daily, 5 days per week; for 2.5 weeks) can penetrate the caseous necrotic lesions in C3HeB/FeJ mice, achieving drug concentrations within the lesions that exceed the free MIC.